Categories

Continuous Glucose Monitor Apps Correction: Dexcom, Inc. Issues Correction for G7 Apps and ONE+ Apps due to a Software Design Error That Does Not Alert Users of Unexpected Sensor Failure

Dexcom is correcting G7 & ONE+ Apps that fail to alert users when sensors fail, potentially causing missed alerts and delayed treatment of hypo/hyperglycemia.

http://www.fda.gov/medical-devices/medical-device-recalls/continuous-glucose-monitor-apps-correction-dexcom-inc-issues-correction-g7-apps-and-one-apps-due

 
Categories

Insulin Pump Correction: Tandem Diabetes Care Issues Correction for Certain t:slim X2 Insulin Pumps Due to Risk for Faulty Speaker Wiring That May Cause Malfunction and Stop Insulin Delivery

t:slim X2 insulin pumps provide insulin to people with diabetes, but a speaker wiring issue may cause an error that makes the pump stop delivering insulin.

http://www.fda.gov/medical-devices/medical-device-recalls/insulin-pump-correction-tandem-diabetes-care-issues-correction-certain-tslim-x2-insulin-pumps-due

 
Categories

BD Provides Update on Voluntary Recall of Certain BD Alaris™ Pump Infusion Sets

FRANKLIN LAKES, N.J. (Sept. 12, 2025) – BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today expanded their Class I voluntary recall initiated in the United States on July 8, 2025 and expanded on July 17, 2025 to inform customers of worst-case performanc

http://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/bd-provides-update-voluntary-recall-certain-bd-alaristm-pump-infusion-sets